Report of the European Medicines Agency Conference on RNA-Based Medicines.
Falk EhmannAndreas KuhnAnna Maria Gerdina PasmooijAnthony HumphreysArjon Van HengelBrian DooleyBrigitte AnlikerCamilla SvenssonDaniel CapaldiDavid HenshallEmer CookeHaiyan ZhouHilde BastaertsJeske SminkJoop Van GervenLeonor EnesLubomir NechevMarcel HoefnagelMariëtte DriessensMichael WengerOriane BlanquiePawel WidomskiRalf HeroldRené ThürmerSol RuizSteffen ThirstrupSusan GoodyTal ZaksValentina CordoʹAnnemieke M Aartsma-RusPublished in: Nucleic acid therapeutics (2024)
RNA-based medicines have potential to treat a large variety of diseases, and research in the field is very dynamic. Proactively, The European Medicines Agency (EMA) organized a virtual conference on February 2, 2023 to promote the development of RNA-based medicines. The initiative addresses the goal of the EMA Regulatory Science Strategy to 2025 to "catalyse the integration of science and technology in medicines development." The conference focused on RNA technologies (excluding RNA vaccines) and involved different stakeholders, including representatives from academia, industry, regulatory authorities, and patient organizations. The conference comprised presentations and discussion sessions conducted by panels of subject matter experts. In this meeting report, we summarize the presentations and recap the main themes of the panel discussions.